CORD-19:185e78aee848db9cc3a4510619048a6e4acd22cc / 18140-18475 JSONTXT

{"project":"CORD-19_Custom_license_subset","denotations":[{"id":"T114","span":{"begin":0,"end":335},"obj":"Sentence"}],"text":"27 The substitution of brentuximab vedotin for bleomycin (A-AVD) was compared with ABVD in patients with stage III/IV cHL in the phase III ECHE-LON-1 study, and resulted in a statistically significant improvement in the primary endpoint of modified progression-free survival at 2 years with no difference in OS at the time of analysis."}

{"project":"CORD-19-Sentences","denotations":[{"id":"TextSentencer_T114","span":{"begin":0,"end":335},"obj":"Sentence"},{"id":"TextSentencer_T114","span":{"begin":0,"end":335},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"27 The substitution of brentuximab vedotin for bleomycin (A-AVD) was compared with ABVD in patients with stage III/IV cHL in the phase III ECHE-LON-1 study, and resulted in a statistically significant improvement in the primary endpoint of modified progression-free survival at 2 years with no difference in OS at the time of analysis."}

{"project":"CORD-19-PD-MONDO","denotations":[{"id":"T178","span":{"begin":65,"end":68},"obj":"Disease"},{"id":"T179","span":{"begin":118,"end":121},"obj":"Disease"}],"attributes":[{"id":"A178","pred":"mondo_id","subj":"T178","obj":"http://purl.obolibrary.org/obo/MONDO_0010518"},{"id":"A179","pred":"mondo_id","subj":"T179","obj":"http://purl.obolibrary.org/obo/MONDO_0009348"}],"text":"27 The substitution of brentuximab vedotin for bleomycin (A-AVD) was compared with ABVD in patients with stage III/IV cHL in the phase III ECHE-LON-1 study, and resulted in a statistically significant improvement in the primary endpoint of modified progression-free survival at 2 years with no difference in OS at the time of analysis."}